Literature DB >> 30245804

A Transdiagnostic Temperament-Phenotype Profile Approach to Emotional Disorder Classification: An Update.

Anthony J Rosellini1,2, Hannah Boettcher1, Timothy A Brown1, David H Barlow1.   

Abstract

Although the emotional disorders (EDs) have achieved favorable reliability in the Diagnostic and Statistical Manual of Mental Disorders (DSM), accumulating evidence continues to underscore limitations in ED diagnostic validity. In particular, taxometric, comorbidity, and other descriptive psychopathology studies of transdiagnostic phenotypes studies suggest that the EDs may be best conceptualized as dimensional entities that are more similar than different. Despite optimism that the fifth edition of the DSM (DSM-5) would constitute a meaningful shift toward dimensional ED assessment and diagnosis, most changes contribute little movement in that direction. In the present report, we summarize past and anticipate persisting (i.e., in DSM-5) limitations of a purely categorical approach to ED diagnosis. We then review our alternative dimensional-categorical profile approach to ED assessment and classification, including preliminary evidence in support of its validity and presentation of two ED profile case examples using our newly developed Multidimensional Emotional Disorder Inventory. We end by discussing the transdiagnostic treatment implications of our profile approach to ED classification and directions for future research.

Entities:  

Keywords:  categorical versus dimensional classification; diagnostic reliability; diagnostic validity; emotional disorders; hybrid dimensional-categorical classification; internalizing disorders; multidimensional emotional disorder inventory; transdiagnostic dimensions; transdiagnostic treatments

Year:  2015        PMID: 30245804      PMCID: PMC6150461          DOI: 10.5127/pr.036014

Source DB:  PubMed          Journal:  J Exp Psychopathol        ISSN: 2043-8087


  44 in total

1.  A taxometric investigation of the latent structure of worry.

Authors:  A M Ruscio; T D Borkovec; J Ruscio
Journal:  J Abnorm Psychol       Date:  2001-08

2.  The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability.

Authors:  J B Williams; M Gibbon; M B First; R L Spitzer; M Davies; J Borus; M J Howes; J Kane; H G Pope; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-08

3.  Major depression and generalised anxiety disorder. Same genes, (partly)different environments--revisited.

Authors:  K S Kendler
Journal:  Br J Psychiatry Suppl       Date:  1996-06

4.  Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample.

Authors:  T A Brown; L A Campbell; C L Lehman; J R Grisham; R B Mancill
Journal:  J Abnorm Psychol       Date:  2001-11

5.  Diagnostic comorbidity in panic disorder: effect on treatment outcome and course of comorbid diagnoses following treatment.

Authors:  T A Brown; M M Antony; D H Barlow
Journal:  J Consult Clin Psychol       Date:  1995-06

6.  Behavioral activation and inhibition systems and the severity and course of depression.

Authors:  Karen L Kasch; Jonathan Rottenberg; Bruce A Arnow; Ian H Gotlib
Journal:  J Abnorm Psychol       Date:  2002-11

7.  The structure and stability of common mental disorders: the NEMESIS study.

Authors:  W A Vollebergh; J Iedema; R V Bijl; R de Graaf; F Smit; J Ormel
Journal:  Arch Gen Psychiatry       Date:  2001-06

8.  Health concerns in patients with obsessive-compulsive disorder.

Authors:  J S Abramowitz; B D Brigidi; E B Foa
Journal:  J Anxiety Disord       Date:  1999 Sep-Oct

9.  DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses.

Authors:  Darrel A Regier; William E Narrow; Diana E Clarke; Helena C Kraemer; S Janet Kuramoto; Emily A Kuhl; David J Kupfer
Journal:  Am J Psychiatry       Date:  2013-01       Impact factor: 18.112

10.  Risk for mania and positive emotional responding: too much of a good thing?

Authors:  June Gruber; Sheri L Johnson; Christopher Oveis; Dacher Keltner
Journal:  Emotion       Date:  2008-02
View more
  6 in total

1.  Efficacy of the Unified Protocol for transdiagnostic treatment of comorbid psychopathology accompanying emotional disorders compared to treatments targeting single disorders.

Authors:  Stephanie Jarvi Steele; Todd J Farchione; Clair Cassiello-Robbins; Amantia Ametaj; Sophia Sbi; Shannon Sauer-Zavala; David H Barlow
Journal:  J Psychiatr Res       Date:  2018-08-03       Impact factor: 4.791

2.  Dealing with complexity and comorbidity: Opportunity for transdiagnostic treatment for PTSD.

Authors:  Cassidy A Gutner; Candice Presseau
Journal:  Curr Treat Options Psychiatry       Date:  2019-05-09

3.  Effortful Control Moderates the Relation Between Negative Emotionality and Child Anxiety and Depressive Symptom Severity in Children with Anxiety Disorders.

Authors:  Elizabeth M Raines; Andres G Viana; Erika S Trent; Haley E Conroy; Karina Silva; Michael J Zvolensky; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2021-07-24

4.  Efficacy of the Unified Protocol for the treatment of comorbid alcohol use and anxiety disorders: Study protocol and methods.

Authors:  Todd J Farchione; Hayley E Fitzgerald; Andrew Curreri; Amy C Janes; Matthew W Gallagher; Sophia Sbi; Elizabeth H Eustis; David H Barlow
Journal:  Contemp Clin Trials       Date:  2021-07-17       Impact factor: 2.261

5.  Emotion-focused therapy as a transdiagnostic treatment for depression, anxiety and related disorders: Protocol for an initial feasibility randomised control trial.

Authors:  Ladislav Timulak; Daragh Keogh; James McElvaney; Sonja Schmitt; Natalie Hession; Katarina Timulakova; Ciaran Jennings; Fiona Ward
Journal:  HRB Open Res       Date:  2020-02-13

6.  Anxiety reduction through art therapy in women. Exploring stress regulation and executive functioning as underlying neurocognitive mechanisms.

Authors:  Annemarie Abbing; Leo de Sonneville; Erik Baars; Daniëlle Bourne; Hanna Swaab
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.